Company intelligence / Profile preview
Assertio
Lake Forest, Illinois, United Statesassertiotx.com ↗
- Ownership
- Public · ASRT
- Employees
- ~58
- Development stage
- Other
01
Overview
Assertio commercializes a portfolio of FDA-approved prescription drugs, including NSAIDs for pain and migraine (Cambia, Zipsor), and via its 2023 Spectrum Pharmaceuticals acquisition, ROLVEDON for chemotherapy-induced neutropenia. Assertio’s legacy neurology/pain franchises have generated stable revenues, but recent growth is driven by business development and oncology entry.
- Therapeutic areas
- OncologyNeurology
- Modalities
- Small moleculeSynthetic glucocorticoid corticosteroidBiologic
- Industry
- Biotech
02
Drug pipeline
35 assets34 more assets in the full pipeline.
03
Partnerships
Collegium Pharmaceutical
Beyond the preview
Go deeper on Assertio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Assertio.